---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000034"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-06-03T20:01:21+00:00"
generated_at: "2026-06-03T20:02:11.612218+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics announces stockholder votes at 2026 annual meeting

## Summary
- Elected Jean-Jacques Bienaimé and Charles Newton as directors with 10,093,559 and 14,716,598 votes for, respectively.
- Ratified Deloitte & Touche LLP as independent auditor for FY 2026 (16,708,279 for, 783,953 against).
- Advisory vote on executive compensation approved (14,273,625 for, 974,049 against).

## SEC filing metadata
- accession: 0001664710-26-000034
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-06-03T20:01:21+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/0001664710-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/kros-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000034
- JSON: https://secwatch.observer/filing/0001664710-26-000034.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000034.txt

## Key facts
- Shareholder Votes
  Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jean-Jacques Bienaimé 10,093,559.27 5,156,153 2,243,514 Charles Newton 14,716,598 533,114 2,243,514
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/0001664710-26-000034-index.htm
- Shareholder Votes
  Keros Therapeutics, Inc. shareholders approved Advisory vote on executive compensation. at the 2026-06-03 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3. The votes cast were as follows: Votes For Votes Against Votes Abstain Broker Non-Votes 14,273,625.27 974,049 2,038 2,243,514
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/0001664710-26-000034-index.htm
- Shareholder Votes
  Keros Therapeutics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 16,708,279.27 783,953 994 There were no broker non-votes with respect to Proposal 2.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/0001664710-26-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.